Science Corporation raises $400m Series D for neural interfaces
The financing supports the PRIMA vision-restoration system and development of biohybrid neural interfaces.
Science Corporation announced a $400 million Series D on November 17. Participants included Khosla Ventures, Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator and PLC Neurotech.
The company develops neural interfaces, including PRIMA, a retinal implant system designed to restore useful vision to people with severe sight loss. The funding supports commercialization of PRIMA and research on biohybrid interfaces that combine living cells with electronics.
PRIMA is commercially available in Europe. Science is pursuing a US humanitarian device exemption from the FDA.
Use of funds
PRIMA availability in Europe
US regulatory preparation
Research manufacturing and operations
Biohybrid neural interfaces